Prentiss Smith & Co’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Prentiss Smith & Co’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,200	Closed	-$56K	–	253
2014 Q1	$56K	Buy	+1,200	New	+$56.7K	0.03%	108

Other funds holding XPH

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

NCM

Niemann Capital Management Stateline, Nevada $788K AUM 23.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Prentiss Smith & Co's XPH Position: Q2 2014 in Review

Prentiss Smith & Co sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2014, closing a stake of 1,200 shares — an estimated $56K sold.

Prentiss Smith & Co first reported a position in XPH in Q1 2014 and held it in 1 quarter. The position peaked at $56K in Q1 2014. 69 funds tracked by Wall St. Rank hold XPH as of Q2 2014.

Prentiss Smith & Co reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2014 after selling out during the quarter.
Prentiss Smith & Co sold 1,200 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2014, an estimated $56K.
Prentiss Smith & Co first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2014 and held it in 1 quarter.
Prentiss Smith & Co's State Street SPDR S&P Pharmaceuticals ETF position peaked at $56K in Q1 2014.
69 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2014.

Based on Prentiss Smith & Co's 13F filing for Q2 2014, filed 23 Jul 2014.